Denali Therapeutics DNLI
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Denali Therapeutics (DNLI) Business Model and Operations Summary
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Key Insights
Denali Therapeutics (DNLI) Core Market Data and Business Metrics
Latest Closing Price
$12.29Market Cap
$1.76 BillionPrice-Earnings Ratio
-4.45Total Outstanding Shares
145.22 Million SharesTotal Employees
422Dividend
No dividendIPO Date
December 8, 2017SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
161 Oyster Point Blvd., South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $493.18 Million |
| Net Cash Flow From Operating Activities, Continuing | $-362.64 Million |
| Net Cash Flow From Investing Activities | $-187.92 Million |
| Net Cash Flow, Continuing | $-57.38 Million |
| Net Cash Flow From Financing Activities, Continuing | $493.18 Million |
| Net Cash Flow | $-57.38 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $504.60 Million |
| Revenues | $14.54 Million |
| Basic Earnings Per Share | $-2.76 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Net Income/Loss Attributable To Parent | $-427.49 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-421.31 Million |
| Other Comprehensive Income/Loss | $-421.31 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $6.18 Million |
| Comprehensive Income/Loss | $-421.31 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $1.45 Billion |
| Liabilities | $135.52 Million |
| Accounts Payable | $9.59 Million |
| Noncurrent Liabilities | $48.42 Million |
| Assets | $1.45 Billion |
| Current Liabilities | $87.09 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||